VJHemOnc is committed to improving our service to you

ASCO 2019 | Selinexor: an underappreciated MM development

VJHemOnc is committed to improving our service to you

Paul Richardson

Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the development of selinexor for the treatment of multiple myeloma at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter